Research use only, not for human consumption. Email [email protected]
← Research status explorer
Enhance / Reproductive & pigmentation

Melanotan I

Also known as: Afamelanotide, Scenesse

Current research status Approved Molecule*
Established pharmaceutical ingredient
Preclinical
Phase 1
Phase 2
Phase 3
Approved Molecule*

Overview

Melanotan I is generally described as chemically identical to afamelanotide (Nle4-D-Phe7-α-MSH), which is FDA-approved as Scenesse since October 2019 specifically to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP). That approval is specific to the Scenesse implant, its dosing and the EPP indication — it is not an approval for tanning or any other cosmetic use, and research-grade Melanotan I should not be assumed to be manufactured or quality-controlled to the same standard as the approved implant.

Last reviewed: September 2026

*Approval refers to specific pharmaceutical products, formulations, jurisdictions and indications containing this molecule. It does not indicate that the Vital Edge Science research product is approved.